Oryn Therapeutics and Keck Medicine of USC will collaborate on a $5.3 M National Institute of Health award to develop new drugs to treat multi-drug resistant bacterial infections. In response to a call to develop novel solutions to the crisis of drug-resistant bacterial infections, scientists at Oryn and USC will join forces to exploit Oryn’s macrocyclic peptide technologies to identify and produce novel drugs that kill pathogens that are increasingly implicated in lethal infections. The collaboration will be led by USC Professor and Oryn co-founder Michael Selsted, USC Professor Andre Ouellette, and Oryn scientists.
- Oryn and University of Southern California Scientists Report Significant Advance in Antifungal Drug Therapy December 4, 2019
- Dalton Announces a Drug Development and GMP Manufacturing Services Agreement with Oryn Therapeutics April 12, 2018
- USC Press release: Oryn and University of Southern California scientists report on first-in-class macrocyclic peptide therapeutic for treatment of rheumatoid arthritis November 30, 2017
- PLoS ONE publication: Oryn and USC collaborators publish in PLoS ONE the application of Orynotides for treatment of evolving and severe rheumatoid arthritis November 29, 2017
- Oryn selected to present at 2016 BIO International Convention June 7, 2016
- Oryn Therapeutics and Keck Medicine of USC RECEIVE $5.3 M NIH award May 17, 2016
- Oryn therapeutics secures $3,000,000 of angel investment September 2, 2015